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1996Objectives: Fiji has one of the highest rates of rheumatic heart disease in the world. Humanitarian fly-in/fly-out
surgical teams, including Open Heart International, have been conducting valve replacement surgery in Fiji
since 1991. We sought to determine the short- and long-term outcomes of valve replacement for rheumatic heart
disease.
Methods: The Open Heart International team performed surgery on 167 patients from 1991 to 2011. Complete
follow-up data to death or last evaluation on 149 patients (89.2%) and morbidity data for 152 patients (91%)
were extracted from medical records.
Results: Patients’ average age at the time of surgery was 26.1 years, with the majority being female (63.5%).
Valves replaced were isolated mitral valves (52%), isolated aortic valves (19%), and multiple valves (29%).
The cumulative mortality rate at 30, 60, and 90 days and at 1, 5, and 10 years was 2.4%, 6.0%, 8.4%,
12.0%, 19.8%, and 23.9%, respectively. Major adverse valve-related events–free survival was 10.1 years
(95% confidence interval [CI], 8.32-11.94). After adjusting for confounders, female patients were 3.03 times
more likely to die postoperatively than male patients (odds ratio [OR], 3.03; 95% CI, 1.23-7.69). Patients
undergoing isolated valve replacement were less likely to have a morbidity event than those undergoing multiple
valve replacement (isolated mitral 67% less likely [OR, 0.33; 95% CI, 0.12-0.93] and isolated aortic 76% less
likely [OR, 0.34; 95% CI, 0.06-0.96]).
Conclusions: The majority of people undergoing valve replacement for rheumatic heart disease have good
outcomes. Mortality and morbidity rates at 1 and 5 years, particularly for female patients, are cause for concern
and indicate a need for evaluation of resources toward systematic long-term postoperative surveillance and
medical management. (J Thorac Cardiovasc Surg 2014;148:1996-2003)Rheumatic heart disease (RHD) is a global health problem
conservatively estimatedas affecting16millionpeopleworld-
wide and continues to be a significant cause of mortality and
morbidity in developing countries.1-3 Some 97% of all
RHD occurs in developing countries and among indigenous
populations of industrialized countries, primarily because
pathogenesis is related to poverty, overcrowding, increased
frequency of bacterial throat and skin infections, and
decreased access to medical care.1,4
In contrast to global trends, data from South Pacific
island countries indicate that the prevalence of RHD
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The Journal of Thoracic and Cardiovascular Sur33.2 per 1000 in the Kingdom of Tonga9 to 55.2 per 1000
in the Fiji Islands.7 Consequently, the Fiji Islands currently
has the highest documented prevalence of RHD in the
world, with children as young as 6 years old having RHD
as the primary cause of death.5,10 Although there are a
number of programs in place to manage and control
RHD in Fiji, including prevention and screening
campaigns,7,11,12 there remains an absence of in-country
capability to provide valve replacement (VR) surgery for
people who have severe RHD.
Strategies implemented in Fiji to provide VR surgery
consist of transporting patients for surgery to other nearby
countries and inviting fly-in/fly-out humanitarian teams
in-country to perform the surgery. The latter is the most
economic option for Fiji because these surgical teams are
able to operate on approximately 8 patients for the same
cost as sending 1 patient overseas for surgery.
VR surgery for RHD is major surgery; up to 3 valves may
be replaced depending on the severity of the disease.13
Surgical risks include increased risk of morbidity or morta-
lity from stroke, embolism, infection, and cardiac failure.13
Mechanical valves are primarily used on fly-in/fly-outgery c November 2014
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CI ¼ confidence interval
CWMH ¼ Colonial War Memorial Hospital
INR ¼ international normalized ratio
MAVE ¼ major adverse valve-related event
MVR ¼ mitral valve replacement
OHI ¼ Open Heart International
OR ¼ odds ratio
RHD ¼ rheumatic heart disease
VR ¼ valve replacement
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Dmissions because they are more durable, although there is an
associated increase in risk of thromboembolic or hemorrhag-
ic events due to the concomitant need for anticoagulation
therapy. In addition, RHD and endocarditis prophylaxis,
and cardiac rhythm and rate control are necessary.14,15 The
risks of anticoagulation therapy are well recognized, with
thromboembolic/hemorrhagic complications most likely to
occur within the first 6 months after a mechanical VR.16
This means that although most patients are able to resume
a fully active life after a 3-month recovery period, lifelong
medical surveillance is required.14 Within this context, eval-
uation of longer-term postoperative outcomes after fly-in/
fly-out VR surgery is warranted.
There are little published data on short- and long-term
follow-up of people who have undergone VR surgery for
RHD disease in the South Pacific region or in other
developing countries that use fly-in/fly-out humanitarian
surgical teams as a key strategy.17,18 This retrospective
study analyzed follow-up data collated from all patients
who have undergone VR surgery for RHD performed by
the Open Heart International (OHI) Team in Fiji (formerly
known as Operation Open Heart) from 1991 to 2011. This
evaluation will assist in identifying risk factors and
facilitate tailoring of postoperative patient education to
match identified needs. National and institutional Human
Research Ethics Committee approval were obtained in
Australia and Fiji before commencement of the study.
The study objectives were to identify the short- and longer-
term outcomes after VR for RHD in Fiji for all-cause mortal-
ity, valve and RHD-related morbidity, and freedom from
major adverse valve-related event (MAVE),19 and to deter-
mine the statistically significant factors associated with all-
cause mortality and valve and RHD-related morbidity for
people after VR surgery for RHD.MATERIALS AND METHODS
Setting and Participants
The Fiji Islands are located in the South West Pacific and are composed
of 332 islands, of which approximately one third are inhabited. The
estimated population of 950,000 is mainly ethnic Fijian (57%) andThe Journal of Thoracic and CarIndo-Fijian (37%), with the remaining 6% including people of Caucasian,
Chinese, and Rotuman ethnicities.20
The OHI humanitarian fly-in/fly-out surgical team is coordinated by the
Sydney Adventist Hospital, located in Sydney, New South Wales,
Australia.21 The team conducts VR surgery at the Colonial War Memorial
Hospital (CWMH), the national referral hospital located in Suva, Fiji.
Screening visits occur before the surgical team visit to evaluate prospective
patients, referred by local physicians, for surgical selection. If screening
indicates surgical need, the OHI cardiologists present the patient’s history
and echocardiograms at a video teleconference in Sydney to key OHI
personnel, including surgeons, anesthetists, cardiac nurses, and the team
leader. Prospective patients selected during the video teleconference are
reevaluated on-site at CWMH before final selection. Dental review and
extraction, if required, occur in-hospital as a component of the preoperative
workup alongside antibiotic prophylaxis. Surgical exclusion criteria
includes irreversible cardiac dysfunction, such as pulmonary hypertension
90 mm Hg or greater and left ventricular ejection fraction 25% or less,
cardiomyopathy, or active endocarditis.
The OHI surgical team aims to complete as many successful surgeries as
clinically possible within a 2-week time-frame and to do so in a
cost-efficient way. Themultidisciplinary team includes 35 to 50 volunteers,
licensed, medical, nursing, allied health, biomedical, and paramedical
personnel and additional staff to manage data, transport, accommodation,
and meals. All OHI staff undergo a police check (criminal record and
working with children) from their home country with temporary ‘‘authority
to practice’’ licensure obtained from the relevant Fijian Professional
Registration boards. The OHI team collaborates with local medical and
nursing staff on patient care provision across all domains of the surgical
process, with training aimed at eventual in situ capability. Funds to cover
the costs of surgery, estimated at $3500 Australian dollars per patient,
are completely met by donations from individual volunteers, medical
companies, civic groups (eg, Rotary International and Lions Clubs
International), and grants from AusAID (disbanded at the end of 2013)
and the local Ministry of Health Fiji.
Operative Process
Over the 20-year time period reported, 19 surgeons conducted the
surgery. A sternotomy approach and standard operative techniques are
used for valve implantation and annuloplasty. Cardiopulmonary bypass is
established on normothermia ormild hypothermia, antegrade or retrograde,
and selective coronary artery retrograde cold blood cardioplegia is used for
myocardial protection. For mitral VRs, the posterior leaflet apparatus is
conserved.Whole blood cardioplegia is used on rewarming. Patients under-
going operation since 1999 (n ¼ 137) had intraoperative transesophageal
echocardiography to confirm diagnoses and to assess valvular and
prosthesis function. The majority (n ¼ 162, 97%) of patients received a
mechanical VR prosthesis. Between 1991 and 2005, all VR prostheses
were from St Jude Medical Inc (St Paul, Minn). From 2006 to 2012,
a combination of ATS (Medtronic Inc, Minneapolis, Minn) (n ¼ 11),
On-X (On-X Life Technologies, Inc) (n ¼ 8), and Edwards Lifesciences
(Irvine, Calif) (n¼ 2) prostheses were used, as well as the St Jude Medical
prostheses. Patients living in remote regions and female patients of child-
bearing age are given the option of a biological prosthesis.
Postoperative Follow-up
The OHI surgical team remains in Suva to provide operative ‘‘on-call’’
for a minimum of 76 hours after the last operation has been performed.
The OHI nursing team continues to work alongside local staff in the
postoperative ward for a further 5 days.
Postoperative thromboprophylaxis is achieved using a combination of
heparin, aspirin, and warfarin. Daily low-dose aspirin and twice-daily sub-
cutaneous unfractionated heparin is administered.Warfarin is added on day
2 postoperatively with the adjunctive thromboprophylaxis continuing until
an international normalized ratio (INR) of 2.0 is achieved. Patients arediovascular Surgery c Volume 148, Number 5 1997
TABLE 1. Demographic and valve replacement characteristics of
people undergoing valve replacement for rheumatic heart disease in
Fiji
Sample
n ¼ 167
Male
n ¼ 61
Female
n ¼ 106 P
value*Mean (SD) Mean (SD) Mean (SD)
Age, y 26.1 (11.7) 23.3 (9.8) 27.7 (12.5) .02
n (%) n (%) n (%)
Ethnicity
Fijian 110 (65.9) 43 (70.5) 67 (63.2) .34
Indo-Fijian or other 57 (34.1) 18 (29.5) 39 (36.8)
Valve replaced
Mitral 87 (52.1) 28 (46.0) 59 (55.6) .22
Aortic 32 (1.2) 17 (27.9) 15 (14.2) .03
Mitral þ aortic 27 (16.2) 12 (19.7) 15 (14.2) .35
Mitral  aortic and
tricuspid ring
annuloplasty
21 (12.5) 4 (6.6) 17 (16.0) .08
SD, Standard deviation. *One-way analysis of variance or chi-square test used for
analysis, as applicable.
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Suva for 6 weeks to attend the CWMH specialized outpatient department
heart clinic for cardiac medication adjustments, INR level checks,
warfarin-dose titration, and RHD prophylaxis. Target INRs are 2.5 to 3.5
for mitral or multiple VR recipients and 2.0 to 3.0 for isolated aortic valve
recipients.14 Dysrhythmias such as atrial fibrillation are managed through
electrolyte replacement and antiarrhythmicmedications. If patients are still
hospitalized when the OHI team leaves, care is transferred to the local med-
ical and nursing team who work alongside the OHI team during their time
in-country. There is local capability to manage prolonged ventilation or
renal failure should this be required.
Standard postoperative instructions included advice on protecting the
sternal split via restrictions on lifting, performing hard manual labor,
gardening, and performing strenuous domestic duties for 3 months
postoperatively. Additional advice included female patients being
instructed to avoid unplanned pregnancy andmale patients being instructed
to avoid all contact sports. Lifelong attendance at a specialized outpatient
department heart clinic is required monthly for anticoagulation monitoring,
warfarin titration, and medication management.
Data-Collection Process
Data collection was undertaken during 6 field trips in-country over a
3-year period from 2009 to 2012. Patient details were obtained from the
OHI Fiji surgical registry. A data-extraction tool was developed for the
project, which included sociodemographic information, mortality, and
morbidity. At the start of each data-collection cycle, patient records
were reviewed at CWMH, and visits were then made to referring
hospitals, specialized outpatient department, and health clinics to extract
additional information. Multiple patient records needed to be tracked,
including accessing the centralized electronic record of patient visits
and localized paper records at CWMH, referring hospitals, additional
treating hospitals, and separate outpatient departments and village health
clinic records. The last known villages of former patients were visited,
and familial and friendship networks were used to locate patients lost to
follow-up.
Complete follow-up data to death or last evaluation were obtained on
89.2% of the sample for a total of 624.9 patient years and a mean of
4.2 years (standard deviation, 4.24). Morbidity data were extracted for
152 patients (91%), with 15 having no evidence of subsequent medical
contact after hospital discharge. There were no statistically significant
differences between the lost to follow-up group and the rest of the sample
in gender, ethnicity, valve position, or operative age (data not shown).
Outcomes
Mortality and morbidity outcome data collected encompassed cerebral
events, bleeding events, infective endocarditis, valve malfunction, sudden
unexplained death, sternal infection, and heart failure. These data were
based on guidelines for reporting morbidity and mortality after cardiac
valve interventions.19 We report any death as ‘‘all-cause mortality’’ and
any sudden, unexpected death or valve-related cause-of death, including
infective endocarditis, as valve-related mortality.19 The causes of mortality
and morbidity were obtained from medical records. MAVE was used to
calculate event-free survival.
Statistical Methods
Comparisons of patient characteristics between groups were performed
using the chi-square test or Fisher exact test where appropriate for categoric
variables. One-way analysis of variance was used to test the continuous
variable (age) against categoric variables. Kaplan–Meir survival curve
actuarial analysis was used to delineate freedom frommortality, morbidity,
and MAVE-free survival. Stratified survival curves were plotted to explore
unadjusted differences for variables of interest, with differences in survival
curves examined using the log-rank test. For multivariate analysis, binary1998 The Journal of Thoracic and Cardiovascular Surlogistic regression was used to identify predictors of mortality and
morbidity, with each analysis adjusting for the following confounders:
age, gender, ethnicity, and valve position. Statistical analyses were
conducted using SPSS (SPSS Inc, Chicago, Ill).22
RESULTS
Sample Characteristics
A total of 167 people underwent VR surgery for RHD
between 1991 and 2011, the most common being isolated
mitral valve replacement (MVR) (52%). The remainder
underwent isolated aortic valve replacement (AVR)
(19%), MVR and AVR (16%), and tricuspid ring
annuloplasty in conjunction with MVR or AVR (13%)
(Table 1). The mean age of the sample was 26 years
(standard deviation, 11.71), and most were female (63%).
Ethnicity was reflective of the general Fijian population,
with approximately two thirds (65.8%) ethnic-Fijian,
29.4% Indo-Fijian, and 4.8% other minority ethnic
groups.16 Female patients were older than male patients
by approximately 4 years (P ¼ .02), and female patients
were less likely to have an isolated AVR compared with
male patients (14.2% vs 27.9%) (P ¼ .03). Twenty-three
post-VR pregnancies were recorded during the 20-year
period, resulting in 13 live births.
Mortality
The overall mortality rate was 25.7% (n ¼ 43), which
peaked at 5 years postoperatively (Table 2). The mean
time to death was 3.2 years (95% confidence interval
[CI], 1.91-4.43), and the mean survival time was 4.2 years
(95% CI, 3.54-4.79). Unadjusted actuarial survival time
was 11.5 years (95% CI, 9.45-13.60) (data not shown).
Early mortality (0-90 days) was 8.4%, and 2 (1.2%) of
these deaths occurred in hospital. Mortality at 30, 60, andgery c November 2014
TABLE 2. Early, mid-term, and late mortality by gender of patients
undergoing valve replacement surgery for rheumatic heart disease in
Fiji
Time
Sample
(n ¼ 167)
Male patients
(n ¼ 61)
Female patients
(n ¼ 106) P
value*,yn (%) n (%) n (%)
Early
30 d 4 (2.4) 1 (1.6) 3 (2.8) .99
60 d 6 (3.6) 0 (0.0) 6 (5.7) .09
90 d 4 (2.4) 2 (3.3) 2 (1.9) .62
Total 14 (8.4) 3 (4.9) 11 (10.4) .22
Mid-term
1 y 6 (3.6) 1 (1.6) 5 (4.7) .42
5 y 13 (7.8) 2 (3.3) 11 (10.4) .10
Total 19 (11.4) 3 (4.9) 16 (15.1) .05
Late
10 y 7 (4.2) 2 (3.3) 5 (4.7) .99
20 y 3 (1.8) 0 (0.0) 3 (2.8) .30
Total 10 (6.0) 2 (3.3) 8 (7.6) .33
Total mortality 43 (25.7) 8 (13.1) 35 (33.0) .005
*Chi-square of Fisher exact test used for analysis, as applicable. yComparison of each
time period by gender.
TABLE 3. Type of morbidity event and mortality cause of death
Event type
Sample
(n ¼ 167)
Male
patients
(n ¼ 61)
Female
patients
(n ¼ 106) P
value*,yn (%) n (%) n (%)
Cerebral event 12 (7.2) 5 (8.2) 7 (6.6) .76
Bleeding event 13 (7.8) 0 (0.0) 13 (12.3) .002
Infective endocarditis 9 (5.4) 4 (6.5) 5 (4.7) .73
Heart failure 8 (4.8) 1 (1.6) 7 (6.6) .26
Sternal infection 1 (0.6) 0 (0.0) 1 (0.9) .99
Total morbidity 43 (25.7) 10 (16.4) 33 (31.1) .04
Cause of deathz
Cerebral event 4 (2.4) 0 (0) 4 (3.8) .99
Hemorrhage 2 (1.2) 0 (0) 2 (1.9) .99
Infective endocarditis 7 (5.0) 3 (4.9) 4 (3.8) .11
Valve malfunction 3 (1.8) 0 (0) 3 (2.8) .99
Heart failure 4 (2.4) 0 (0) 4 (3.8) .99
Cardiogenic shock 5 (3.0) 1 (1.6) 4 (3.8) .99
Sudden unexplained death 12 (7.2) 3 (4.9) 9 (8.5) .67
Unknown or other
noncardiac cause
6 (3.6) 1 (1.6) 5 (4.7) .99
Total mortality 43 (25.7) 8 (13.1) 35 (33.0) .005
*Chi-square of Fisher exact test used for analysis, as applicable. yComparison of each
type of morbidity event and cause of death by gender. zPatients who died also may
have had an admission for a morbidity event.
Thomson Mangnall et al Acquired Cardiovascular Disease
A
C
D90 days was 2.4%, 3.6%, and 2.4%, respectively. Overall
mid-term mortality (91 days to 5 years) was 11.4%, and
late mortality (5.01-20 years) was 6%. Although one third
(n ¼ 14, 32.5%) of all 43 deaths occurred in the early
postoperative period (0-90 days), a further 6 deaths
occurred by the 1-year mark so that approximately half of
all deaths occurred in the first postoperative year (n ¼ 20,
46.5%). From 1 to 5 years postoperatively, a further 13
deaths occurred so that two thirds of all mortality occurred
within the first 5 years after surgery (n ¼ 33, 76.7%).
Themost common cause of death was infective endocarditis
followed by cardiogenic shock and cerebral events
(Table 3). However, one quarter (n ¼ 12, 27.9%) of the
43 patients who died had a ‘‘sudden unexplained death.’’
Female patients were more likely to die than male
patients (33% vs 13%, P ¼ .005), particularly at
mid-term (15.1% vs 4.9%, P ¼ .05). Comparison of
actuarial survival by gender (Figure 1, A) showed a
significant difference with estimated mean survival for
male patients of 13.0 years (95% CI, 10.70-15.23) versus
9.9 years (95% CI, 7.80-12.47) for female patients
(P ¼ .009).Morbidity
Valve and RHD-related morbidity occurred in 25.7% of
the sample (Table 4), with more than half of the 43 events
occurring within the first postoperative year (n ¼ 24,
55.8%). The mean time to event was 2.6 years (95% CI,
1.39-3.83). On unadjusted actuarial analysis, freedom
from event time was 11.2 years (95% CI, 9.52-12.96).
Overall, early morbidity was 11.4%, with 9 of these eventsThe Journal of Thoracic and Caroccurring in hospital (5.4%). Morbidity at 30, 60, and 90
days was 6.6%, 3.0%, and 1.8%, respectively. Mid-term
morbidity was 10.8%, and late morbidity was 3.6%.
Bleeding and cerebral events were the most common cause
of morbidity followed by infective endocarditis and heart
failure (Table 3). One patient required ongoing ventilation
and renal dialysis and was transferred to Australia for
treatment.
Survival analysis by gender showed a significant
difference (P ¼ .04) in mean time of freedom from event
with men at 12.5 years (95% CI, 10.30-14.76) and for
women at 10.2 years (95% CI, 8.12-12.29) (Figure 1, B).
Women had significantly more bleeding events than men
(12.3% vs 0%, P ¼ .002) overall and during the early
postoperative period (P< .001), as well as more cerebral
events at this time than men (P ¼ .01) (data not shown).
Throughout mid- and late-term, women had significantly
more readmissions for heart failure (P < .001 and
P ¼ .02), with men having more cerebral events
(P¼ .005) in the late postoperative period (data not shown).
Freedom From Major Adverse Valve-Related Event
Unadjusted survival analysis showed a mean time for
freedom from MAVE as 10.1 years (95% CI, 8.3-11.9)
(data not shown). Female patients had a significantly
shorter freedom from event time (mean, 9.1 years; 95%
CI, 7.01-11.29 years) than male patients (mean, 11.4 years;
95% CI, 8.96-13.76 years) (P ¼ .02).diovascular Surgery c Volume 148, Number 5 1999
FIGURE 1. A, Cumulative survival by gender postoperatively. B, Cumulative morbidity-free survival by gender postoperatively.
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By using logistic regression analysis and taking into
account the type of valve surgery, age, and cultural2000 The Journal of Thoracic and Cardiovascular Surbackground, the only independent predictor of mortality
was gender. Women were 3 times more likely to die in
the long-term after surgery than men (odds ratio [OR],
3.03; 95% CI, 1.23-7.69). Undergoing an isolated MVRgery c November 2014
TABLE 4. Early, mid-term, and late morbidity of patients undergoing
valve replacement surgery for rheumatic heart disease in Fiji
Time
Sample
(n ¼ 167)
Male patients
(n ¼ 61)
Female
patients (n¼106) P
value*,yn (%) n (%) n (%)
Early
30 d 11 (6.6) 2 (3.3) 9 (8.5) .16
60 d 5 (3.0) 0 (0) 5 (4.7) .16
90 d 3 (1.8) 2 (3.3) 1 (0.9) .56
Total 19 (11.4) 4 (6.5) 15 (14.1) .14
Mid-term
1 y 5 (3.0) 1 (1.6) 4 (3.8) .65
5 y 13 (7.8) 3 (4.9) 10 (9.4) .23
Total 18 (10.8) 4 (6.5) 14 (13.2) .18
Late
10 y 3 (1.8) 2 (3.2) 1 (0.9) .56
20 y 3 (1.8) 0 (0) 3 (2.8) .30
Total 6 (3.6) 2 (3.2) 4 (3.8) .99
Total morbidity 43 (25.7) 10 (16.4) 33 (31.1) .04
*Chi-square of Fisher exact test used for analysis, as applicable. yComparison of each
time period by gender.
Thomson Mangnall et al Acquired Cardiovascular Disease
A
C
Dor AVR was an independent predictor of reduced morbidity.
The likelihood of a patient undergoing MVR having a
morbidity event was 67% less (OR, 0.33; 95% CI,
0.12-0.93) and of a patient undergoing AVR was 76%
less (OR, 0.34; 95% CI, 0.06-0.96) than those who
underwent VR surgery that included a tricuspid ring
annuloplasty.DISCUSSION
This is the first study to evaluate long-term follow-up
after VR for RHD in the South Pacific, a region that has
some of the highest rates of RHD in the world.2,6-8,10
Within the context of high rates of premature mortality
caused by RHD and limited access to valvular surgical
intervention in Fiji, it is indisputable that fly-in/fly-out VR
surgery provides the opportunity for a longer lifespan than
would occur without intervention. However, aspects related
to causes of morbidity and mortality and the increased
vulnerability of female patients to both are concerning.
Although the overall and sequential mortality andmorbidity
rates are comparable to VR data from the United States,
the average age of people in this study at 26 years is consid-
erably younger than US samples.23 Clearly, the potential
benefits of VR surgery for resuming a productive life
must be weighed against the morbidity and mortality risks,
particularly because these are predominantly young people
entering the most productive years of their lives.
It is well recognized that the highest risk time period for
anticoagulation-related complications is within the first
year after mechanical VR surgery,16 which is evident in
this study. Approximately half of all mortality and
morbidity occurred in the first postoperative year, and theThe Journal of Thoracic and Carcauses were commonly thromboembolic and hemorrhagic.
These outcomes are likely to be related to the availability of
resources for surveillance and monitoring. One of the
primary reasons that fly-in/fly-out teams are used in Fiji is
the absence of cardiothoracic surgical resources. With a
population of only 1 million and limited resources,
countries like Fiji must always consider the benefits of
fly-in/fly-out programs versus establishing in situ cardiac
surgery services. Consequently, the patients in this Fijian
sample are followed up at general heart clinics across the
country rather than specialized cardiac-surgical clinics.
There remains no formalized follow-up for nonattendance
at clinic and no central point for ongoing referral,
surveillance, and management of VR-related concerns.
As new-generation anticoagulant therapies evolve, oral
alternatives to warfarin such as dabigatran (Pradaxa,
Boehringer Ingelheim, Ingelheim am Rhein, Germany), a
direct thrombin inhibitor, which do not require ongoing
regular INR testing and titration, may be considered.24
Currently, dabigatran has not been approved for use in
VR anticoagulation regimens and is more expensive than
warfarin.
Comparable VR populations who are served by fly-in
fly-out teams are largely unpublished; however, in situ
programs conducted in Pakistan and West Africa25-27 have
lower rates of mortality and morbidity but also have
strictly supervised follow-up regimens that encompass
anticoagulation monitoring and titration, RHD, and
endocarditis prophylaxis prevention, and are managed by
experienced cardiac clinicians. In these studies, patients
received formal discharge education regarding anticoagula-
tion management and RHD prophylaxis, echocardiograms
at 3 months, and 1 year postdischarge thence annually,
and close surveillance of subsequent INR levels. In the
West African study,27 all VR surgery was performed in
Ghana with many patients living more than 100 km from
the facility. Regular follow-up was achieved by having
INRs attended at the patient’s local facilities with warfarin
dosage titration managed by telephone consultation and
reattendance at the Ghanaian clinic every 12 weeks, instead
of the usual 4 weeks. The comprehensive educational and
follow-up programs discussed in these studies provide
feasible strategies for long-term surveillance that would
serve as good models for other developing countries, such
as Fiji, because of similarities in patient type, access, and
resource limitations. One of the most important aspects of
such systematic approaches is that RHD is more likely to
be detected and treated early. Valve damage may then be
less extensive and valve repair more possible than in the
current study, therefore limiting the need for anticoagula-
tion and associated risks.
Female patients were identified to be at a higher risk of
mortality and morbidity, particularly related to bleeding
events. Potential explanation lies in a combination ofdiovascular Surgery c Volume 148, Number 5 2001
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gender-specific issues arising out of mechanical prosthesis
implantation and anticoagulation in women (menstruation,
pregnancy, childbirth), and traditional gender roles for
women in Fiji.28 Although there have been many positive
changes in the country, the disparity between genders on
measurable factors such as paid employment and education
levels is high.29 The traditional female role is secondary and
includes responsibility for domestic-linked domains,
including child-rearing and home duties, regardless of
concomitant paid employment.28 It is probable that familial
and social obligations intertwined with transport costs and
the substantial amount of time required away from home
or employment to attend the monthly clinic may be
obstacles to accessing continued care and influence the
poorer outcomes for female patients in this study. Poverty
also may be an important factor with a study of barriers to
accessing health care by women, undertaken in the
neighboring Pacific country of Vanuatu, identifying the
economic status of the household to which women belong
as a key factor predictive of healthcare use.30 Women living
in poorer households were 5 times less likely to access
health care than those who were relatively affluent.30
Further research evaluating regularity of clinic atten-
dance and access, household income, and other factors,
including more detailed clinical data, is required to identify
reasons for increased female vulnerability to negative
outcomes. In particular, outcomes for women who are
pregnant need to be determined as a basis for further debate
around the choice of valve prosthesis or repair given the
risks women face during pregnancy and childbirth when
taking anticoagulant medication.
The causes of morbidity in this study were closely aligned
with the causes of mortality, and as previously discussed, pa-
tients would benefit from additional surveillance along with
education for both patients and health staff. Ideally, this
would include predischarge education on RHD prophylaxis,
dental interventions and endocarditic prophylaxis, the impor-
tance of maintaining therapeutic anticoagulation and regular
follow-up checks at clinic, and advice on conception and
pregnancy management. Collaboration between the surgical
team and the local medical team to more closely support
long-term follow-up is essential and could be incorporated
into local systems for RHD surveillance and treatment. Inex-
pensive options, such as mobile technology (group text
messaging) currently used by the Fiji Ministry of Health to
obtain volunteers for blood-bank donations, could be used
to support follow-up.
Study Limitations
This study identified having an isolated VR as an
independent predictor of a decreased risk of morbidity.
The need for multiple VR is indicative of the severity of
the RHD, and physiologic cardiac function is generally2002 The Journal of Thoracic and Cardiovascular Surmore compromised.13 However, without precise, docu-
mented echocardiographic data with which to evaluate
disease severity, this explanation is speculative.
Data collection was dependent on the information
available in the medical records. Important data on echo-
cardiographic findings, preoperative and postoperative
functional status, long-term INR, and medication records
were unavailable. Although patients may have had an
echocardiogram, the results were not documented
consistently. In addition, having a large number of deaths
as ‘‘sudden and unexpected’’ without having an identified
cause has reduced the ability to fully evaluate the causes
of death and consequently accurately compare the ‘‘cause
of death’’ outcomes from this study with those of other
populations.17,25-27,31-33CONCLUSIONS
This study shows that the majority of people undergoing
VR surgery for RHD in Fiji by the OHI have good
outcomes. Improvement in discharge education, ongoing
support, long-term surveillance, particularly for female
patients, and appropriate anticoagulation management is
required. Resources need to be prioritized toward closer
long-term medical surveillance because there is evidence
from other studies that better outcomes after VR surgery
are achievable. Future research should include prospective
data collection on important cardiac function parameters
and potentially preventable mortality and morbidity events.
Such research should include specific data on echocardiog-
raphy measures, preoperative and postoperative functional
status, and INR levels over time to enable exploration of
the relative contribution of these to postoperative outcomes.References
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